High Concordance of ALK Rearrangement Between Primary Tumor and Paired Metastatic Lymph Node in Patients with Lung Adenocarcinoma

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2016 Jun 14

PMID 27293826

Citations 12

Authors

Likun Hou

Shengxiang Ren

Bo Su

Liping Zhang

Wei Wu

Wei Zhang

Zhengwei Dong

Yan Huang

Chunyan Wu

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer has heterogeneous features. It remains unclear whether ALK rearrangement was distributed heterogeneously in tumor from different anatomic sites. To address this issue, we investigate the concordance of ALK rearrangement between primary tumors and paired metastatic lymph nodes in pulmonary adenocarcinoma patients.

Methods: From Sep 2013 to May 2014, resectable lung adenocarcinoma patients with EGFR wildtype and paired metastatic lymph nodes from Tongji University affiliated Shanghai pulmonary hospital were selected into this study. An auto-mated Ventana ALK with clone D5F3 antibody immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR) were used to detected ALK rearrangement. Discordant cases between IHC and RT-PCR were further validated by fluorescence in situ hybridization (FISH).

Results: A total of 101 patients were enrolled into this study with a median age of 60 years old (range, 35-78 years). ALK rearrangement was found in 20 primary lesions, while in 18 paired metastatic lymph nodes. ALK rearrangement was more frequently happened in younger (P<0.001), Nonsmokers (P=0.012), high-stage disease (P=0.021) and predominantly solid growth pattern (P=0.024). The concordance rate between primary tumor and paired metastatic lymph nodes was 98%. Two patients with ALK rearrangement on primary tumor didn't show ALK gene fusion on paired metastatic lymph nodes. Sixty-eight cases had more than two stations of metastatic lymph nodes. ALK rearrangement in the different station of metastatic lymph nodes of the same patient was consistent.

Conclusions: High concordant rate of ALK rearrangement between primary tumors and paired metastatic lymph nodes were found in this study. The authors concluded that specimens from metastatic lesions and primary tumors are equally suitable for detection ALK rearrangement.

Citing Articles

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review.

Iannantuono G, Riondino S, Sganga S, Roselli M, Torino F Int J Mol Sci. 2022; 23(7).

PMID: 35409355 PMC: 8999731. DOI: 10.3390/ijms23073995.

Chr1 , a novel intergenic fusion identified in a patient with lung adenocarcinoma with nodular ground-glass opacity.

Chen Q, Yan Y, Yang C, Liu G, Wang G, Li S J Thorac Dis. 2021; 13(7):4618-4622.

PMID: 34422387 PMC: 8339741. DOI: 10.21037/jtd-21-689.

The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma.

Heriyanto D, Trisnawati I, Kumara E, Laiman V, Yuliani F, Sumpono A Pulm Med. 2021; 2020:3578748.

PMID: 33425389 PMC: 7773471. DOI: 10.1155/2020/3578748.

[Research Progress in Consistency of Driver Gene Status between Primary and Corresponding Metastatic Lesions in Non-small Cell Lung Cancer].

Zhou B, Xiong J Zhongguo Fei Ai Za Zhi. 2020; 23(3):196-203.

PMID: 32102137 PMC: 7118335. DOI: 10.3779/j.issn.1009-3419.2020.03.10.

ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.

Bi R, Bai Q, Zhu X, Tu X, Cai X, Jiang W Diagn Pathol. 2019; 14(1):96.

PMID: 31455365 PMC: 6712650. DOI: 10.1186/s13000-019-0864-7.

References

Ren S, Chen X, Kuang P, Zheng L, Su C, Li J . Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer. 2012; 118(22):5588-94. DOI: 10.1002/cncr.27603. View

Camidge D, Bang Y, Kwak E, Iafrate A, Varella-Garcia M, Fox S . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13(10):1011-9. PMC: 3936578. DOI: 10.1016/S1470-2045(12)70344-3. View

Zhang Y, Jin M, Li L, Zhao H, Zeng X, Jiang L . Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS One. 2013; 8(5):e64821. PMC: 3669339. DOI: 10.1371/journal.pone.0064821. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Wang J, Dong Y, Cai Y, Zhou L, Wu S, Liu G . Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. J Cancer Res Clin Oncol. 2014; 140(3):453-60. DOI: 10.1007/s00432-014-1584-8. View

Khode R, Larsen D, Culbreath B, Parrish S, Walker K, Sayage-Rabie L . Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol. 2013; 121(7):361-9. DOI: 10.1002/cncy.21273. View

Kim H, Xu X, Yoo S, Sun P, Jin Y, Paik J . Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. Histopathology. 2012; 62(2):305-14. DOI: 10.1111/j.1365-2559.2012.04356.x. View

Betz B, Dixon C, Weigelin H, Knoepp S, Roh M . The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. Cancer Cytopathol. 2013; 121(9):489-99. DOI: 10.1002/cncy.21286. View

Gow C, Chang Y, Hsu Y, Tsai M, Wu C, Yu C . Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2008; 20(4):696-702. DOI: 10.1093/annonc/mdn679. View

10.

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V . Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2009; 99(6):923-9. PMC: 2538768. DOI: 10.1038/sj.bjc.6604629. View

11.

Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L . Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. J Clin Oncol. 2015; 33(32):3701-9. PMC: 4770798. DOI: 10.1200/JCO.2014.58.8293. View

12.

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

13.

Gruber K, Kohlhaufl M, Friedel G, Ott G, Kalla C . A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry. J Thorac Oncol. 2015; 10(4):713-6. DOI: 10.1097/JTO.0000000000000427. View

14.

Wang W, Tang Y, Li J, Jiang L, Jiang Y, Su X . Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Cancer Cytopathol. 2014; 123(2):117-22. DOI: 10.1002/cncy.21510. View

15.

Wong D, Leung E, So K, Tam I, Sihoe A, Cheng L . The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115(8):1723-33. DOI: 10.1002/cncr.24181. View

16.

Ren S, Hirsch F, Varella-Garcia M, Aisner D, Boyle T, Zhou C . Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014; 9(3):e21-3. PMC: 4117236. DOI: 10.1097/JTO.0000000000000013. View

17.

Han X, Zhang N, Ma L, Lin D, Hao X, Liu Y . Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch. 2013; 463(4):583-91. DOI: 10.1007/s00428-013-1472-7. View

18.

Takeuchi K, Choi Y, Soda M, Inamura K, Togashi Y, Hatano S . Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008; 14(20):6618-24. DOI: 10.1158/1078-0432.CCR-08-1018. View

19.

Wynes M, Sholl L, Dietel M, Schuuring E, Tsao M, Yatabe Y . An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014; 9(5):631-8. PMC: 4186652. DOI: 10.1097/JTO.0000000000000115. View

20.

Sakurada A, Lara-Guerra H, Liu N, Shepherd F, Tsao M . Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol. 2008; 3(5):527-9. DOI: 10.1097/JTO.0b013e318168be93. View